for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study start
estimated completion



The purpose of this study is to evaluate the clinical performance of the i-STAT TBI test for the proposed intended use; to assist in determining the need for a CT scan in patients presenting with suspected mild traumatic brain injury who are 18 years of age or older. The secondary objective of this study is the collection of additional data and specimens from all study subjects that may support other purposes related to the understanding of TBI.


Traumatic Brain Injury, i-STAT, Biomarkers, Brain Injuries, Traumatic Brain Injuries, Blood Draw Within 12 Hours of Injury, 3T MRI, In-Person Outcome Assessment at Baseline, In-Person Outcome Assessment at Follow-Up, Phone Outcome Assessment, Blood Draw After 12 Hours of Injury, Acute Blood Biomarker Branch


For people ages 18 years and up

Acute Blood Biomarker Branch Subject Inclusion Criteria:

  1. 18 years of age or older.
  2. Subject or Legally Authorized Representative (LAR) provided informed consent for the Acute Blood Biomarker Branch (waiver of consent may be acceptable, per IRB).
  3. Subject presented to a health care facility or emergency department with a suspected traumatic brain injury resulting from an insult to the head by an external force within 12 hours of the injury.
  4. Subject has a computed tomography (CT) scan of the head with all sequences (bone and soft tissue) ordered as part of standard of care at the enrolling facility, or are transferred to the enrolling facility with a head CT scan sent from the originating facility.
  5. As a result of this head injury, the subject has sustained a traumatically induced physiological disruption of brain function, as manifested by at least one of the following:
    1. Any period of loss of consciousness
    2. Any loss of memory for events immediately before or after the injury
    3. Any alteration of mental state at the time of the injury
    4. Focal neurological deficits that may or may not be transient

Acute Blood Biomarker Branch Subject Exclusion Criteria:

  1. Previous enrollment in this study, CS-2018-0009
  2. Current (on-going) enrollment in a therapeutic or interventional clinical trial (drug or device)
  3. Primary diagnosis at the enrolling facility of ischemic or hemorrhagic stroke
  4. Time of injury is unknown and cannot be estimated
  5. Presented with penetrating head trauma or spinal cord injury (American Spinal Injury Association [ASIA] score of C or worse) at the enrolling facility
  6. Standard of care head CT scan procedures not completed prior to Emergency Department (ED) discharge.
  7. Prisoners or patients in custody
  8. Patients on psychiatric hold

Follow-up Branch Subject Inclusion Criteria:

  1. Enrollment in Acute Blood Biomarker Branch
  2. Subject or LAR provided informed consent for the Acute Blood Biomarker Branch and the Follow-up Branch

Follow up Branch Subject Exclusion Criteria:

  1. Conditions or circumstances that would interfere with follow-up and outcome assessment, as determined by the principal investigator or delegate. Examples include:
  2. Significant polytrauma
  3. Major debilitating baseline mental health disorders (e.g. schizophrenia or bipolar disorder)
  4. Major debilitating neurological disease (e.g. stroke, cerebrovascular accident, dementia, tumor)


  • UCSF
    San Francisco California 94110 United States
  • University of Utah
    Salt Lake City Utah 84131 United States


accepting new patients by invitation only
Start Date
Completion Date
Abbott Point of Care
Study Type
Expecting 1100 study participants
Last Updated